Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Monday April 15 2019, @10:22PM   Printer-friendly
from the YADIDNKE-Yet-Another-Disease-I-Did-Not-Know-Existed dept.

Promising Results with Givosiran in Acute Hepatic Porphyrias[*]

Investigational givosiran met the primary endpoint of reduction in the annualized rate of composite porphyria attacks versus placebo in patients with acute hepatic porphyria (AHP), researchers said here.

In the interim analysis of the phase III ENVISION trial, patients treated with givosiran experienced a mean composite annualized rate of 3.2 attacks versus 12.5 attacks in patients on placebo (P<0.0001), for a mean reduction of 74%, said Manisha Balwani, MD, of the Mount Sinai School of Medicine in New York City, and colleagues.

"We saw a robust treatment effect," said Balwani at a press conference at the European Association for the Study of the Liver (EASL) annual meeting.

"Currently, there are no approved therapies aimed at preventing the painful, often incapacitating attacks, and chronic symptoms associated with acute hepatic porphyria," she added. "The results from ENVISION are promising and demonstrate a strong treatment effect for givosiran, with reduction of attacks and improvement in patient-reported measures of overall health status and quality of life."

[*] Porphyria.

BBC has a dumbed down article: Gene-silencing: 'New class' of medicine reverses disease porphyria


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0) by Anonymous Coward on Tuesday April 16 2019, @03:31PM (4 children)

    by Anonymous Coward on Tuesday April 16 2019, @03:31PM (#830437)

    It is a "Randomized, Double-blind, Placebo-Controlled" trial and the numbers are in TFA, so feel free to run your own analysis.

    About 50% of the treatment group had porphyria attacks, while about 80% of the placebo group had porphyria attacks. By numbers of porphyria attacks: "mean composite annualized rate of 3.2 attacks versus 12.5 attacks" in the treatment vs. placebo, respectively.

  • (Score: -1, Troll) by Anonymous Coward on Tuesday April 16 2019, @03:51PM (3 children)

    by Anonymous Coward on Tuesday April 16 2019, @03:51PM (#830442)

    While study enrollment has been completed with 94 patients in 18 countries and at 36 sites, the interim analysis

    There you go, p-hacked. They waited until the results looked good, then published something.

    • (Score: 0) by Anonymous Coward on Tuesday April 16 2019, @04:50PM (2 children)

      by Anonymous Coward on Tuesday April 16 2019, @04:50PM (#830469)

      You clearly do not know what you are talking about.

      The study is not over, but the primary outcome measure has been reported and will not change: "The annualized rate of porphyria attacks in patients with AIP. [Time Frame: at 6 months]"

      Actual Study Start Date: November 16, 2017
      Actual Primary Completion Date: January 31, 2019
      Estimated Study Completion Date: September 2021"

      https://clinicaltrials.gov/ct2/show/NCT03338816 [clinicaltrials.gov]

      • (Score: 0) by Anonymous Coward on Tuesday April 16 2019, @05:08PM (1 child)

        by Anonymous Coward on Tuesday April 16 2019, @05:08PM (#830482)

        Meh, don't care enough to puzzle out if this "interim analysis" was pre-planned or not. There isn't even a paper published.

        • (Score: 0) by Anonymous Coward on Tuesday April 16 2019, @05:17PM

          by Anonymous Coward on Tuesday April 16 2019, @05:17PM (#830485)

          The primary outcome measures had to be declared before starting the trial. I've only heard of one or two cases where the primary outcome measures have been updated mid-trial and they need a very good reason why the new outcome measure is better.

          Also, any analysis done before the trial is completed will be "interim" regardless of the fact that the data will not change (there will not be any additional patients or changes to the primary outcome measure).